
    
      This clinical trial will be open label, flexible dose study of Divalproex ER vs Quetiapine
      for 6 weeks. Patients will be randomized to Divalproex ER vs Quetiapine outpatient /
      inpatient. The schedule of visits will include a screening, a baseline and 3 treatment visits
      / assessment. The End of Study/Early Termination visit will conclude the Trial. The safety
      follow-up visit will be scheduled only for the patients with unresolved Adverse Events
      detected prior or at the End of Study/Early Termination visit.
    
  